Targeted cancer therapy

References

• Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011; 17:1674 - 1683; PMID: 21307148; http://dx.doi.org/10.1158/1078-0432.CCR-10-2922
   PubMed Web of Science ®Google Scholar
• Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17:1658 - 1663; PMID: 21447722; http://dx.doi.org/10.1158/1078-0432.CCR-10-0174
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 2516; PMID: 21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408 - 2417; PMID: 17151364; http://dx.doi.org/10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14:2895 - 2899; PMID: 18483355; http://dx.doi.org/10.1158/1078-0432.CCR-07-2248
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Cancer: mixing cocktails. Nature 2007; 449:993 - 996; PMID: 17960228; http://dx.doi.org/10.1038/449993a
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575 - 586; PMID: 21575859; http://dx.doi.org/10.1016/j.ccr.2011.04.008
   PubMed Web of Science ®Google Scholar
• Alberghina L, Hofer T, Vanoni M. Molecular networks and system-level properties. J Biotechnol 2009; 144:224 - 233; PMID: 19616593; http://dx.doi.org/10.1016/j.jbiotec.2009.07.009
   PubMed Web of Science ®Google Scholar
• Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nature reviews. Nat Rev Clin Oncol 2011; 8:280 - 291
   PubMed Web of Science ®Google Scholar
• Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990; 345:544 - 547; PMID: 2348862; http://dx.doi.org/10.1038/345544a0
   PubMed Web of Science ®Google Scholar
• Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332 - 337; PMID: 15029198; http://dx.doi.org/10.1038/nature02369
   PubMed Web of Science ®Google Scholar
• Livingstone M, Atas E, Meller A, Sonenberg N. Mechanisms governing the control of mRNA translation. Phys Biol 2010; 7:21001; PMID: 20463379; http://dx.doi.org/10.1088/1478-3975/7/2/021001
   PubMed Web of Science ®Google Scholar
• Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects on mRNA discrimination, cellular growth rate and oncogenesis. Prog Nucleic Acid Res Mol Biol 1993; 46:183 - 219; PMID: 8234784; http://dx.doi.org/10.1016/S0079-6603(08)61022-3
   PubMed Web of Science ®Google Scholar
• Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20:265 - 273; PMID: 12741684; http://dx.doi.org/10.1023/A:1022943419011
   PubMed Web of Science ®Google Scholar
• Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21:3232 - 3237; PMID: 18055695; http://dx.doi.org/10.1101/gad.1604407
   PubMed Web of Science ®Google Scholar
• Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208:1799 - 1807; PMID: 21859846; http://dx.doi.org/10.1084/jem.20110846
   PubMed Web of Science ®Google Scholar
• Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 1997; 8:1371 - 1380; PMID: 9419425
   PubMedGoogle Scholar
• Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679 - 683; PMID: 18716624; http://dx.doi.org/10.1038/nature07260
   PubMed Web of Science ®Google Scholar
• Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118:2651 - 2660; PMID: 18551192
   PubMed Web of Science ®Google Scholar
• Schatz JH. Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology and Development Strategies. Curr Oncol Rep 2011; 13:398 - 406; PMID: 21755275; http://dx.doi.org/10.1007/s11912-011-0187-7
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17:1841 - 1854; PMID: 12869584; http://dx.doi.org/10.1101/gad.1105003
   PubMed Web of Science ®Google Scholar
• Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105:4477 - 4483; PMID: 15705789; http://dx.doi.org/10.1182/blood-2004-09-3706
   PubMed Web of Science ®Google Scholar
• Gómez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, Martinez-Climent JA, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011; In press PMID: 21937691; http://dx.doi.org/10.1182/blood-2011-03-344374
   PubMed Web of Science ®Google Scholar
• Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, et al. Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell 2011; 147:107 - 119; PMID: 21962511; http://dx.doi.org/10.1016/j.cell.2011.07.049
   PubMed Web of Science ®Google Scholar
• Klein IA, Resch W, Jankovic M, Oliveira T, Yamane A, Nakahashi H, et al. Translocation-Capture Sequencing Reveals the Extent and Nature of Chromosomal Rearrangements in B Lymphocytes. Cell 2011; 147:95 - 106; PMID: 21962510; http://dx.doi.org/10.1016/j.cell.2011.07.048
   PubMed Web of Science ®Google Scholar
• Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, et al. Antitumor activity and mechanism of action of the cyclopenta[b] benzofuran, silvestrol. PLoS ONE 2009; 4:5223; PMID: 19401772; http://dx.doi.org/10.1371/journal.pone.0005223
   PubMed Web of Science ®Google Scholar